STEEPLE bleeding criteria: Difference between revisions
Line 8: | Line 8: | ||
<ref name="pmid19171853">{{cite journal| author=Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al.| title=Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. | journal=Circulation | year= 2009 | volume= 119 | issue= 5 | pages= 680-6 | pmid=19171853 | doi=10.1161/CIRCULATIONAHA.108.803528 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19171853 }} </ref> | <ref name="pmid19171853">{{cite journal| author=Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al.| title=Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. | journal=Circulation | year= 2009 | volume= 119 | issue= 5 | pages= 680-6 | pmid=19171853 | doi=10.1161/CIRCULATIONAHA.108.803528 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19171853 }} </ref> | ||
*'''Major Bleeding''' | *'''Major Bleeding''' | ||
Fatal [[bleeding]] | * Fatal [[bleeding]] | ||
Retroperitoneal, intracranial, or [[intraocular bleeding]] | * Retroperitoneal, intracranial, or [[intraocular bleeding]] | ||
Bleeding that causes hemodynamic compromise requiring specific treatment | * Bleeding that causes hemodynamic compromise requiring specific treatment | ||
Bleeding that requires intervention (surgical or endoscopic) or decompression of a closed space to stop or control the event | * Bleeding that requires intervention (surgical or endoscopic) or decompression of a closed space to stop or control the event | ||
Clinically overt bleeding, requiring any transfusion of ≥1 U PRBC or whole blood | * Clinically overt bleeding, requiring any transfusion of ≥1 U PRBC or whole blood | ||
Clinically overt bleeding, causing a decrease in hemoglobin of ≥3 g/dL (or, if hemoglobin level is not available, a decrease in | * Clinically overt bleeding, causing a decrease in hemoglobin of ≥3 g/dL (or, if hemoglobin level is not available, a decrease in hematocrit of ≥10%) | ||
hematocrit of ≥10%) | |||
*'''Minor''' | *'''Minor''' | ||
Gross [[hematuria]] not associated with [[trauma]] (eg, from instrumentation) | Gross [[hematuria]] not associated with [[trauma]] (eg, from instrumentation) | ||
[[Epistaxis]] that is prolonged, is repeated, or requires plugging or intervention | [[Epistaxis]] that is prolonged, is repeated, or requires plugging or intervention | ||
Gastrointestinal hemorrhage | Gastrointestinal hemorrhage | ||
[[Hemoptysis]] | * [[Hemoptysis]] | ||
[[Subconjunctival hemorrhage]] | * [[Subconjunctival hemorrhage]] | ||
[[Hematoma]] >5 cm or leading to prolonged or new hospitalization | * [[Hematoma]] >5 cm or leading to prolonged or new hospitalization | ||
Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL | Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL | ||
Uncontrolled bleeding requiring protamine sulfate administration}} | Uncontrolled bleeding requiring protamine sulfate administration}} |
Revision as of 17:31, 27 March 2013
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
STEEPLE bleeding criteria On the Web |
American Roentgen Ray Society Images of STEEPLE bleeding criteria |
Risk calculators and risk factors for STEEPLE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Steeple Bleeding Criteria
“ |
Safety and Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation [1]
Gross hematuria not associated with trauma (eg, from instrumentation) Epistaxis that is prolonged, is repeated, or requires plugging or intervention Gastrointestinal hemorrhage
Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL Uncontrolled bleeding requiring protamine sulfate administration |
” |
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial". Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.